MBX Biosciences, Inc./$MBX

13:30

15:10

16:45

18:25

20:00

1D1W1MYTD1Y5YMAX

About MBX Biosciences, Inc.

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Ticker

$MBX

Sector

Health Care

Primary listing

NASDAQ

Industry

Pharmaceuticals

Headquarters

Carmel, United States

Employees

ISIN

US55287L1017

Website

mbxbio.com

MBX Metrics

BasicAdvanced

$448M

-

-$3.93

-

Bulls say / Bears say

MBX Biosciences' lead candidate, MBX 2109, is in Phase 2 trials for chronic hypoparathyroidism, addressing a significant unmet medical need. (stockanalysis.com)

Analysts have set an average 12-month price target of $37.40 for MBX, indicating a potential upside of approximately 199%. (stockanalysis.com)

The company recently submitted an IND for MBX 4291, a GLP1/GIP receptor co-agonist prodrug targeting obesity, expanding its pipeline into a lucrative market. (mbxbio.com)

MBX reported a net loss of $73.47 million over the trailing twelve months, highlighting ongoing financial challenges. (stockanalysis.com)

The stock has experienced significant volatility, with a 52-week range between $4.81 and $27.50, indicating potential instability. (stockanalysis.com)

As a clinical-stage company, MBX faces inherent risks associated with drug development, including potential trial failures and regulatory hurdles. (stockanalysis.com)

Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

MBX News

AllArticlesVideos

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

GlobeNewsWire·3 weeks ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

GlobeNewsWire·4 weeks ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MBX

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for MBX Biosciences, Inc. stock?

MBX Biosciences, Inc. (MBX) has a market cap of $448M as of July 16, 2025.

What is the P/E ratio for MBX Biosciences, Inc. stock?

The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of July 16, 2025.

Does MBX Biosciences, Inc. stock pay dividends?

No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of July 16, 2025.

When is the next MBX Biosciences, Inc. dividend payment date?

MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.

What is the beta indicator for MBX Biosciences, Inc.?

MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.